Roche's recent decision to return the rights to UCB’s anti-tau antibody bepranemab comes after a four-year investment in the Alzheimer's disease drug candidate, which was initially valued at up to $2 billion in milestones. This strategic move happens just before the release of phase 2a data for the
In recent years, the pharmaceutical and biotechnology sectors have experienced a dynamic landscape in mergers and acquisitions (M&A). From major multimillion-dollar deals to strategic acquisitions targeting high-demand therapeutic areas, the industry has witnessed fluctuations driven by various
Quantum BioPharma Ltd. (NASDAQ: QNTM) is making strategic moves to enhance its presence in the health and wellness sector through its subsidiary, Celly Nutrition Corp. Celly Nutrition has clinched a Master Distribution Agreement with FUSION Consulting Group for its innovative product, Unbuzzd.
The biotech industry is bustling with innovation and potential, and Xeris Biopharma Holdings Inc (NASDAQ: XERS) is making waves. This article aims to delve deep into the nuts and bolts of Xeris Biopharma’s recent market activities, financial health, insider trading, analysts' ratings, valuation
The biopharma sector is facing a significant wave of layoffs in 2024, affecting thousands of employees across various companies. This trend is shaped by numerous internal and external factors, including corporate restructuring, market adaptations, strategic divestments, and cost-saving measures.
The biotechnology industry is currently experiencing a wave of renewed interest, particularly in the field of immunology. A shining example of this trend is Upstream Bio, a Massachusetts-based firm that recently made headlines with its $255 million initial public offering (IPO). The substantial
